In our earlier work, we measured CD4+ and CD8+ T cell responses in a cohort of average, non-hospitalized cases of COVID-19 during the convalescent phase as a first benchmark of ADIMs to SARS-CoV-2 (Grifoni et al., 2020a). The gene discussed is CD8A; the disease is COVID-19.